KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $602.0 million.

  • Pfizer's Capital Expenditures fell 6977.91% to $602.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year decrease of 1373.09%. This contributed to the annual value of $2.9 billion for FY2024, which is 2554.39% down from last year.
  • Latest data reveals that Pfizer reported Capital Expenditures of $602.0 million as of Q3 2025, which was down 6977.91% from $618.0 million recorded in Q2 2025.
  • Over the past 5 years, Pfizer's Capital Expenditures peaked at $2.2 billion during Q4 2022, and registered a low of $537.0 million during Q3 2021.
  • Its 5-year average for Capital Expenditures is $965.8 million, with a median of $727.5 million in 2022.
  • In the last 5 years, Pfizer's Capital Expenditures skyrocketed by 14592.59% in 2024 and then tumbled by 6977.91% in 2025.
  • Pfizer's Capital Expenditures (Quarter) stood at $1.7 billion in 2021, then surged by 30.78% to $2.2 billion in 2022, then crashed by 53.29% to $1.0 billion in 2023, then surged by 90.8% to $2.0 billion in 2024, then crashed by 69.78% to $602.0 million in 2025.
  • Its last three reported values are $602.0 million in Q3 2025, $618.0 million for Q2 2025, and $564.0 million during Q1 2025.